<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003404</url>
  </required_header>
  <id_info>
    <org_study_id>D9801 CDR0000066410</org_study_id>
    <secondary_id>P30CA023108</secondary_id>
    <secondary_id>DMS-9801</secondary_id>
    <secondary_id>DMS-12752</secondary_id>
    <secondary_id>NCI-V98-1442</secondary_id>
    <nct_id>NCT00003404</nct_id>
  </id_info>
  <brief_title>Radiation Therapy After Surgery in Treating Women With Phyllodes Tumor of the Breast</brief_title>
  <official_title>A Prospective Study of Adjuvant Radiation Therapy After Resection of Borderline and Malignant Phyllodes Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      PURPOSE: This phase II trial studied how well radiation therapy works after surgery in
      treating women with phyllodes tumor of the breast.

      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Radiation therapy
      following surgery may be effective in treating patients with phyllodes tumor of the breast.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the local recurrence rate in women with phyllodes tumors of the breast
           previously treated with local excision with negative margins and are now treated with
           adjuvant radiotherapy.

        -  Determine the survival rate in patients treated with this regimen.

      METHODS: Within 12 weeks after prior local excision or breast reexcision, patients underwent
      adjuvant radiotherapy 5 days a week for a total of 28 treatments. Patients were then followed
      every 6 months for 10 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1998</start_date>
  <completion_date type="Actual">November 17, 2008</completion_date>
  <primary_completion_date type="Actual">November 17, 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Recurrence Rate</measure>
    <time_frame>36 months after initial excision</time_frame>
    <description>Local recurrence rate of phyllodes tumors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival Rate</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Survival will be tracked for 10 years after initial resection of first participant treated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Adjuvant Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant radiation was started within 12 weeks of local excision or breast re-excision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Adjuvant Radiotherapy</intervention_name>
    <description>Adjuvant radiation therapy</description>
    <arm_group_label>Adjuvant Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          1. Histologically proven phyllodes tumors of the breast with borderline or malignant
             grade, defined as 1 of the following:

               1. Borderline, defined as 5-9 mitoses/10 high power fields (HPF), pushing or
                  infiltrating margins, 2+ atypia

               2. Malignant, defined as 10 or more mitoses/10 HPF, predominantly infiltrating
                  margins, usually 3+ atypia with occasional 2+ atypia

          2. Must have been excised with breast-conserving resection and no positive margins

          3. Local recurrence of a previously excised phyllodes tumor allowed if the recurrence is
             in the area of the prior excision

          4. No prior breast carcinoma or ductal carcinoma in situ in the ipsilateral breast

          5. Hormone receptor status: Not specified

        PATIENT CHARACTERISTICS:

          1. Age: 18 and over

          2. Sex: Female

          3. Menopausal status: Not specified

          4. Performance status: Not specified

          5. Life expectancy: Not specified

          6. Hematopoietic: Not specified

          7. Hepatic: Not specified

          8. Renal: Not specified

          9. Other:

               1. Not pregnant

               2. Negative pregnancy test

               3. Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

          1. Biologic therapy: Not specified

          2. Chemotherapy: Not specified

          3. Endocrine therapy: Not specified

          4. Radiotherapy: No prior radiotherapy to the ipsilateral breast

          5. Surgery: See Disease Characteristics
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard J. Barth, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Norris Cotton Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Barth RJ Jr, Wells WA, Mitchell SE, Cole BF. A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol. 2009 Aug;16(8):2288-94. doi: 10.1245/s10434-009-0489-2. Epub 2009 May 8.</citation>
    <PMID>19424757</PMID>
  </results_reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>October 3, 2018</results_first_submitted>
  <results_first_submitted_qc>December 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2019</results_first_posted>
  <last_update_submitted>December 30, 2018</last_update_submitted>
  <last_update_submitted_qc>December 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Richard J. Barth,Jr.</investigator_full_name>
    <investigator_title>Chief, Section of General Surgery</investigator_title>
  </responsible_party>
  <keyword>recurrent breast cancer</keyword>
  <keyword>phyllodes tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phyllodes Tumor</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled from a total of 30 different institutions. Half of the patients were treated at community-based treatment centers, and half were treated at academic medical centers.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Adjuvant Radiotherapy</title>
          <description>Adjuvant radiation was started within 12 weeks of local excision or breast re-excision.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adjuvant Radiotherapy</title>
          <description>Adjuvant radiation was started within 12 weeks of local excision or breast re-excision.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="18" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Local Recurrence Rate</title>
        <description>Local recurrence rate of phyllodes tumors</description>
        <time_frame>36 months after initial excision</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adjuvant Radiotherapy</title>
            <description>Adjuvant radiation was started within 12 weeks of local excision or breast re-excision.
Adjuvant Radiotherapy: Adjuvant radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Local Recurrence Rate</title>
          <description>Local recurrence rate of phyllodes tumors</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>rate of occurance</param_type>
            <param_value>0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>8</ci_upper_limit>
            <estimate_desc>The local recurrence rate was estimated by dividing the number of recurrences by the total sample size. An exact 95% confidence interval (95% CI) for this rate was determined by binomial distribution.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival Rate</title>
        <description>Survival will be tracked for 10 years after initial resection of first participant treated.</description>
        <time_frame>Approximately 5 years</time_frame>
        <population>All patients received adjuvant radiotherapy as specified in the protocol. No patients were lost to follow-up. Duration of follow-up ranged from 12 to 129 months, with a median follow-up of 56 months and a mean follow-up of 60 months. Ninety percent of the patients were followed for at least 2 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvant Radiotherapy</title>
            <description>Adjuvant radiation after local excision or breast re-excision.</description>
          </group>
        </group_list>
        <measure>
          <title>Survival Rate</title>
          <description>Survival will be tracked for 10 years after initial resection of first participant treated.</description>
          <population>All patients received adjuvant radiotherapy as specified in the protocol. No patients were lost to follow-up. Duration of follow-up ranged from 12 to 129 months, with a median follow-up of 56 months and a mean follow-up of 60 months. Ninety percent of the patients were followed for at least 2 years.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Adjuvant Radiotherapy</title>
          <description>Adjuvant radiation after local excision or breast re-excision.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard J. Barth Jr., MD</name_or_title>
      <organization>Dartmouth Hitchcock Medical Center</organization>
      <phone>(603) 650-9479</phone>
      <email>Richard.J.Barth.Jr@hitchcock.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

